מכפיל EV/EBITDA Quest Diagnostics Incorporated (DGX)

The EV/EBITDA multiple on the time chart in the GURU.Markets terminal demonstrates the strategy of Quest Diagnostics (DGX) to capture market share by acquiring loss-making laboratories and implementing AI-driven tests. Large-scale robotization of sample sorting and digital data analysis optimize processes. The 14.90 metric indicates the status of a company whose revenue relies on stable settlements with US insurance behemoths and hospitals.

Investors are assessing the resilience of Quest Diagnostics (DGX) through the lens of debt load and operational efficiency. The multiple correlates the total enterprise value, including debt, with earnings before interest, taxes, depreciation, and amortization, revealing the asset's true value. Analyzing the business valuation via the EV/EBITDA ratio provides insight into how the company withstands the pressure of government tariffs and competition from startups. Low values may signal either an undervaluation or systemic risks within the model.